Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 3/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29307110 | 0.87 | PDK2 (0.48) | CDC25BCDC25AHSD17B10ALDH1A1ATM | |
| SCHEMBL29114 | 0.85 | PDK2 (0.58) | ATMPDK2 | |
| SCHEMBL134286 | 0.85 | PDK2 (0.58) | ATMPDK2 | |
| SCHEMBL134285 | 0.85 | PDK2 (0.58) | ATMPDK2 | |
| SCHEMBL2381120 | 0.85 | CDC25B (0.55) | CDC25BCDC25AHSD17B10ALDH1A1AKR1C3 | |
| SCHEMBL1552743 | 0.84 | PDK2 (0.66) | ALDH1A1ATMPDK2LMNACYP2C8 | |
| SCHEMBL133477 | 0.84 | PDK2 (0.66) | ALDH1A1ATMPDK2LMNACYP2C8 | |
| SCHEMBL14124721 | 0.84 | SMN1; SMN2 (0.49) | CDC25BCDC25AHSD17B10ALDH1A1AKR1C3 | |
| SCHEMBL12337045 | 0.84 | PDK2 (0.60) | ALDH1A1ATMPDK2CYP2C8CYP2C9 | |
| SCHEMBL5846670 | 0.84 | PDK2 (0.55) | PDK2POLBCYP2C8CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014104666-A1 | INK COMPOSITION FOR ORGANIC ELECTRONIC ELEMENT, AND ORGANIC ELECTRONIC ELEMENT USING SAME | 주식회사 두산 (KR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014104666-A1 | INK COMPOSITION FOR ORGANIC ELECTRONIC ELEMENT, AND ORGANIC ELECTRONIC ELEMENT USING SAME | 주식회사 두산 (KR) | 2014-07-03 | — | — | WO | disclosed |
| US-8395144-B2 | Anthracene derivatives and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8395144-B2 | Anthracene derivatives and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8395144-B2 | Anthracene derivatives and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2011-03-10 | — | — | US | disclosed |
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2011-03-10 | — | — | US | disclosed |
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2011-03-10 | — | — | US | disclosed |
| WO-2009139580-A2 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 (KR) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139580-A2 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 (KR) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110057182-A1 | ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | TRPA1, AHR, ORAI2 | CDC25B 2498/4885CDC25A 2826/4885HSD17B10 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.